Linked e-resources
Details
Table of Contents
Intro; Series Editor Foreword; Preface; Contents; Contributors; Part I: Embryologic and Genetic Disorders of the Pituitary Gland; Chapter 1: Embryologic and Genetic Disorders of the Pituitary Gland; Hypothalamo-Pituitary Development; Human Conditions Arising from Disordered Hypothalamo-Pituitary Development; Isolated Growth Hormone Deficiency; Other Isolated Hormone Deficiencies and Abnormalities; Septo-Optic Dysplasia; HESX1; SOX2 and SOX3; OTX2; GLI2; Pituitary Stalk Interruption Syndrome; ARNT2; PNPLA6; KCNQ1; IFT172; References; Chapter 2: Genetics of Hypopituitarism; Case Presentation
Introduction and Clinical Presentation of Hormone DeficienciesPROP1; POU1F1 (PIT1); Case Continued; Future Considerations; References; Part II: Acquired Pituitary Disorders: Pituitary Tumors and Nonpituitary Sellar Masses; Chapter 3: Adamantinomatous Craniopharyngioma: Genomics, Radiologic Findings, Clinical, and Prognosis; Introduction; Epidemiology; Molecular Aetiology of ACP; Mouse Models of ACP Demonstrate a Causative Role of CTNNB1 Mutations; Sox2+ Pituitary Stem Cells Can Induce Tumour Formation in a Paracrine Manner; Imaging Studies; Presenting Clinical Manifestations
Risk-Adapted Treatment StrategiesSurgery; Radiooncological Treatment; Instillation of Sclerosing Substances for Cystic Tumours; Long-Term Outcome and Morbidities; Pituitary Deficiencies; Visual and Neurological Outcomes; Hypothalamic Syndrome; Challenges in Treating Hypothalamic Obesity; Eating Behaviour; Sequelae, Prognosis, and Quality of Life; Quality of Life, Neurocognitive Outcome, and Psychosocial Functioning; Cerebrovascular Morbidity; Second Malignant Neoplasms; Survival and Late Mortality; Conclusions; References; Chapter 4: Prolactinomas; Introduction and Epidemiology
Presenting Signs and Symptoms of ProlactinomasDiagnostic Approach; Laboratory Evaluation; Evaluation of Elevated Serum Prolactin; Diagnostic Pitfalls in Prolactin Measurement; Considerations in Prolactin Measurement; Falsely Low Prolactin Due to Hook Effect; Macroprolactinemia; Pituitary MRI; Ophthalmological Referral; Consideration of Genetic Testing; Management; Laboratory Evaluation; Observation Without Dopamine Agonist Therapy; Dopamine Agonist Therapy; Adverse Effects; Monitoring Dopamine Agonist Therapy; Weaning Dopamine Agonist Therapy; Surgical Therapy; Other Treatments; Prognosis
Introduction and Clinical Presentation of Hormone DeficienciesPROP1; POU1F1 (PIT1); Case Continued; Future Considerations; References; Part II: Acquired Pituitary Disorders: Pituitary Tumors and Nonpituitary Sellar Masses; Chapter 3: Adamantinomatous Craniopharyngioma: Genomics, Radiologic Findings, Clinical, and Prognosis; Introduction; Epidemiology; Molecular Aetiology of ACP; Mouse Models of ACP Demonstrate a Causative Role of CTNNB1 Mutations; Sox2+ Pituitary Stem Cells Can Induce Tumour Formation in a Paracrine Manner; Imaging Studies; Presenting Clinical Manifestations
Risk-Adapted Treatment StrategiesSurgery; Radiooncological Treatment; Instillation of Sclerosing Substances for Cystic Tumours; Long-Term Outcome and Morbidities; Pituitary Deficiencies; Visual and Neurological Outcomes; Hypothalamic Syndrome; Challenges in Treating Hypothalamic Obesity; Eating Behaviour; Sequelae, Prognosis, and Quality of Life; Quality of Life, Neurocognitive Outcome, and Psychosocial Functioning; Cerebrovascular Morbidity; Second Malignant Neoplasms; Survival and Late Mortality; Conclusions; References; Chapter 4: Prolactinomas; Introduction and Epidemiology
Presenting Signs and Symptoms of ProlactinomasDiagnostic Approach; Laboratory Evaluation; Evaluation of Elevated Serum Prolactin; Diagnostic Pitfalls in Prolactin Measurement; Considerations in Prolactin Measurement; Falsely Low Prolactin Due to Hook Effect; Macroprolactinemia; Pituitary MRI; Ophthalmological Referral; Consideration of Genetic Testing; Management; Laboratory Evaluation; Observation Without Dopamine Agonist Therapy; Dopamine Agonist Therapy; Adverse Effects; Monitoring Dopamine Agonist Therapy; Weaning Dopamine Agonist Therapy; Surgical Therapy; Other Treatments; Prognosis